According to a recent study, a combination of dupilumab and abrocitinib is effective in treating refractory atopic dermatitis (AD) in pediatric patients.
top of page
it's where dermatology lives
bottom of page
According to a recent study, a combination of dupilumab and abrocitinib is effective in treating refractory atopic dermatitis (AD) in pediatric patients.
Comments